Skip to Content
  • Blog Housekeeping

    Catching Up

    Little time for blogging the last day or two. I’ve been finishing up a paper to send to Bioorganic and Medicinal Chemistry Letters, the first one I’ve written in a while, and I’m checking over another paper that I’m a coauthor on. We’re deciding on where to send that one – the lead author suggested… Read More
  • Clinical Trials

    More From the Me-Too Front

    Some interesting mail has come in after last week’s post on comparative clinical trials. Reader C.B. that I spoke about here some time ago, but should have raised again: “It seems to me that something else is being left out: not all patients respond the same way to any particular drug. . . Suppose that… Read More
  • Clinical Trials

    Putting A Price on Proving It

    I’ve already had some reader mail (see here) about this article in today’s New York Times. It starts out looking like a real pharma-bashing exercise. Up to a point, it is – and up to a point, it’s deserved, too. But in the end it’s a more subtle piece, not that you’d guess that from… Read More
  • Cardiovascular Disease

    Ezetimibe, The Press, and More

    Credit where it’s due! Yesterday I mentioned the original chemist who started the ezetimibe story, but I should note that the drug itself was synthesized by another former colleague of mine, Stuart Rosenblum. He and a host of others developed a huge series of analogs, which built in more acitivity and greater in vivo stability. Read More
  • Cardiovascular Disease

    The Beginning? It’s Right Past the End. . .

    There’s a paper in the latest issue of Science from a team at Schering-Plough that may have tracked down how the company’s cholesterol absorption inhibitor (Zetia, ezetimibe) works. That news really takes me back. It’s been years now, so it won’t do any harm to mention that I used to work there. I had a… Read More
  • Drug Prices

    One Of Us Is Hallucinating

    I’ve been involved in the comments section of another blog, a discussion of pharmaceutical prices which took off from the posts over here. Things have taken a turn that I didn’t expect, so I thought I’d run it past the readers of this site. There’s a specific misapprehension that I’m running into, one that I’ve… Read More
  • Drug Prices

    Reimportation’s Just the Beginning

    Here are some interesting points raised by reader Duane Oyen, from e-mail and quoted by permission “I think that any reimportation scheme has to be done on the basis (honest basis, not demagogic political windbaggery, which is where it usually ends up) of free trade- thus causing ME to “get to” YOU- because of the… Read More
  • One Of Us Is Hallucinating

    I’ve been involved in the comments section of another blog, a discussion of pharmaceutical prices which took off from the posts over here. Things have taken a turn that I didn’t expect, so I thought I’d run it past the readers of this site. There’s a specific misapprehension that I’m running into, one that I’ve… Read More
  • All Fixed Up

    Time to revisit a long-standing topic. You may well have noticed the news items about the FDA’s new programs to crack down on prescription drug counterfeiting. That sort of crime is to be expected, given the money to be made – although you really have to wonder about the human status of anyone who turns… Read More
  • Drug Assays

    How Drugs Die

    Everyone in the industry would like to do something about the failure rate of drugs in clinical trials. It would be far better to have not spent the time and money on these candidates, and the regret just increases as you move further down the process. A Phase I failure is painful; a Phase III… Read More
...531532533...